Abbott Completes Enrollment in Cardiac Study
Posted on: Thursday, 31 August 2006, 09:00 CDT
Abbott has completed enrollment in a study to identify and predict patient risk for future cardiac events.
The study will focus on "vulnerable" plaque, a lipid-rich coronary plaque that suddenly ruptures, believed to be the cause of most heart attacks. The study enrolled 700 acute coronary syndrome patients in the US and Europe. Patients will be followed up for at least two, and up to five, years.
The study utilizes novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.
Dr Gregg Stone, principal investigator of the study will present data from the first group of patients enrolled in October at the Eighteenth Annual Scientific Symposium in Washington, D.C.
Source: Datamonitor
Related Articles
- Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- Aspirin-Resistant Patients at Heart Risk
- Study: Lipitor Slashes Heart, Stroke Risk
- Most with heart risk don't use aspirin: study
- Scientist: Vioxx study showed no increased risk
- Study: Antidepressants Reduce Heart Risk
- Merck Canceled Project to Study Heart Risks of Vioxx in 2002
- Study Finds Celebrex Heart Risk ; Pfizer Doesn't Plan Recall, but Prescription Cut Seen
- Recall Rattles Patients ; Vioxx Heart Risk Should Vanish By Discontinuing Use of Drug, Local Physician Says.
 |
 |
User Comments (0)
RSS Feeds